GSK1120212, soluble in DMSO and insoluble in ethanol and water, prevents the phosphorylation and activation of ERK leading to reduced cell proliferation and induced apoptosis in cancerous cells. It targets MEK1 and MEK2.
GSK1120212 (Trametinib) can be used to investigate the inhibition of MEK1 and MEK2 in the MAPK/ERK signaling pathway, which is often implicated in cancer.
Publications
Publications (0)
×
Publications
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.